Sign Out
Data of ZANIDIP provide no evidence of teratogenic effect in the rat and the rabbit, and the reproductive performance in the rat was unimpaired. Nevertheless, since there is no clinical experience with ZANIDIP in pregnancy and lactation, and other dihydropyridine compounds have been found teratogenic in animals.
ZANIDIP should not be administered during pregnancy or to women with child-bearing potential unless effective contraception is used. Because of high lipophilicity of lercanidipine, distribution in milk may be expected. Therefore it should not be administered to nursing mothers.
